Oblit­er­at­ed by Alzheimer's fail­ure, Neu­rotrope re­lin­quish­es its Nas­daq spot in re­verse merg­er

Bat­tered af­ter a spec­tac­u­lar fail­ure with its Alzheimer’s drug can­di­date, Neu­rotrope Bio­sciences is be­ing ab­sorbed by a pri­vate­ly-held com­pa­ny that makes an erec­tile dys­func­tion …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER